Return to homepagePandemic Pact

Glasgow Early Treatment Arm Favipiravir (GETAFIX): a randomised controlled study favipiravir as an early treatment arm of ASTERIX in Covid-19 Hospitalised patients

Grant number: COV/GLA/20/03

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $194,072.4

  • Funder

    CSO Scotland

  • Principal Investigator

    Janet Scott

  • Research Location

    United Kingdom

  • Lead Research Institution

    University of Glasgow

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Favipiravir is used in Japan to treat influenza and can kill SARS-CoV2 in the laboratory4. The drug is safe in healthy volunteers and reached concentrations in the body needed to kill the virus. In China, 35 COVID-19 patients treated with Favipiravir recovered in 4 days compared to those treated with Lopinavir/ritonavir (45 patients) who took 11 days. We propose to treat COVID-19 patients with Favipiravir to see if it improves their chances of recovery without needing admission to intensive care, study what happens once Favipiravir is metabolised by the body, and check for drug resistance.

Publicationslinked via Europe PMC

Last Updated:14 hours ago

View all publications at Europe PMC

Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial.